Back to Journals » Clinical Interventions in Aging » Volume 10

Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med

Authors Zhang LT, Lee SW, Park K, Chung WS, Kim SW, Hyun JS, Moon DG, Yang SK, Ryu JK, Yang DY, Moon KH, Min KS, Park JK

Received 10 September 2014

Accepted for publication 20 October 2014

Published 17 January 2015 Volume 2015:10 Pages 277—286

DOI https://doi.org/10.2147/CIA.S74102

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Richard Walker

Li Tao Zhang,1 Sung Won Lee,2 Kwangsung Park,3 Woo Sik Chung,4 Sae Woong Kim,5 Jae Seog Hyun,6 Doo Geon Moon,7 Sang-Kuk Yang,8 Ji Kan Ryu,9 Dae Yul Yang,10 Ki Hak Moon,11 Kweon Sik Min,12 Jong Kwan Park1

1Department of Urology, Chonbuk National University, Medical School and Biomedical Research Institute and Clinical Trial Center for Medical Devices of Chonbuk National University Hospital, Jeonju; 2Department of Urology, College of Medicine, Sungkyunkwan University, Seoul; 3Department of Urology, College of Medicine, Chonnam National University, Gwangju; 4Department of Urology, College of Medicine, Ewha Woman’s University, Seoul; 5Department of Urology, College of Medicine, Catholic University, Seoul; 6Department of Urology, College of Medicine, Kyungsang National University, Jinju; 7Department of Urology, College of Medicine, Korea University, Seoul; 8Department of Urology, Chungju Hospital, College of Medicine, Konkuk University, Chungju; 9Department of Urology, College of Medicine, Inha University, Incheon; 10Department of Urology, College of Medicine, Hallym University, Seoul; 11Department of Urology, College of Medicine, Youngnam University, Daegu; 12Department of Urology, College of Medicine, Inje University, Busan, Republic of Korea

Background: The objective of this study was to assess the efficacy and safety of alfuzosin 10 mg monotherapy or combined antihypertensive medication on blood pressure (BP) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) with or without antihypertensive medication.
Methods: This was a 3-month, multicenter, randomized, open-label study in 335 patients aged ≥45 years with a clinical diagnosis of BPH/LUTS by medical history and clinical examination, a total International Prostatic Symptom Score (IPSS) ≥8 points, a maximum flow rate >5 mL/sec and ≤15 mL/sec, and a voided volume ≥120 mL. Eligible subjects were randomized to receive alfuzosin 10 mg as monotherapy (group 1) or alfuzosin 10 mg + antihypertensive combination therapy (group 2). Based on baseline BP and hypertensive history with or without antihypertensive medications at first medical examination, group 1 was divided into two subgroups of normotensive and untreated hypertensive patients, and group 2 into two subgroups of controlled hypertensive and uncontrolled hypertensive patients. The primary study outcomes were change in IPSS, BP, and heart rate from baseline. Secondary outcomes were change in IPSS-quality of life score, maximum flow rate, average flow rate, voided volume, and post-voided volume.
Results: The overall BP change was not significantly different between groups 1 and 2 (systolic BP, P=0.825; diastolic BP, P>0.999). In patients with uncontrolled or untreated hypertension, alfuzosin 10 mg alone or combined with antihypertensive therapy significantly decreased systolic and diastolic BP. The mean difference in total IPSS and IPSS-quality of life scores from baseline between groups 1 and 2 was 0.45 (95% CI: −1.26, 2.16) and 0.12 (95% CI: −0.21, 0.45), respectively (both P>0.05). Maximum flow rate, average flow rate, voided volume, and post-voided volume at endpoint were numerically, but not significantly, changed from baseline (all P>0.05).
Conclusion: This study shows that alfuzosin 10 mg is effective and well tolerated in patients with BPH/LUTS with or without antihypertensive medications. However, in patients with uncontrolled or untreated hypertension, alfuzosin 10 mg alone or in combination with antihypertensive medication appears to decrease systolic and diastolic BP, and these patients should be warned about a decrease in BP on initiation of therapy.

Keywords: alfuzosin, lower urinary tract symptoms, benign prostatic hyperplasia, antihypertensive medication, blood pressure

A Letter to the Editor has been received and published for this article.

 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway

Soni KK, Shin YS, Choi BR, Karna KK, Kim HK, Lee SW, Kim CY, Park JK

Drug Design, Development and Therapy 2017, 11:2969-2979

Published Date: 11 October 2017

Dose-dependent effects of cisplatin on the severity of testicular injury in Sprague Dawley rats: reactive oxygen species and endoplasmic reticulum stress

Soni KK, Kim HK, Choi BR, Karna KK, You JH, Cha JS, Shin YS, Lee SW, Kim CY, Park JK

Drug Design, Development and Therapy 2016, 10:3959-3968

Published Date: 12 December 2016

Prospective investigation of change in the prostate-specific antigens after various urologic procedures

Park SC, Shin YS, Zhang LT, Kim DS, Kim SZ, Park NC, Ahn TY, Kim JJ, Lee SW, So I, Park JK

Clinical Interventions in Aging 2015, 10:1213-1218

Published Date: 29 July 2015

Readers of this article also read:

Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia

Riva S, Nobili A, Djade CD, Mancuso ME, Santagostino E, Pravettoni G

Clinical Interventions in Aging 2015, 10:1141-1146

Published Date: 9 July 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010